AstraZeneca said on Monday it was in talks that might lead to the acquisition of privately held biotech firm Acerta Pharma, a potential $5 billion-plus deal designed to build up its cancer drug portfolio.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
